Tirzepatide
The one with depth behind it. If the question is how a dual receptor approach behaves over long study periods, this is where the published record is thickest, including a head to head against the leading single receptor compound.
North & North · Peptide Catalog
Tirzepatide vs Retatrutide
Two receptors, or three
Same family, one real difference. Tirzepatide works two receptors at once and has years of published trials behind it. Retatrutide works three, and the third one is the part that made everyone look twice. Both are here, in both sizes.
The actual difference
It Comes Down to One Receptor
Two receptors, or three. That is the entire difference, and the third one is stranger than it sounds.
Both act on the same two gut hormone receptors, the ones your body already uses to respond to a meal. Tirzepatide stops there, and that pairing is what made it the reference point everything else gets compared against. Retatrutide adds glucagon, which does the opposite of what you would expect: it raises blood sugar. That reads backwards until you know the other half, which is that it also raises how much energy the body burns. The other two receptors work against the blood sugar side, so what is left is the energy side. More receptors is not automatically better. It is different, and it is newer.
Side by side
How They Compare
| Comparison point | Tirzepatide | Retatrutide |
|---|---|---|
| Receptors | Two. GIP and the incretin receptor. | Three. Those two, plus glucagon. |
| How much research exists | A lot, and it is mature. Large trials have been reporting since 2022. | Growing fast. A large Phase 3 program has been reporting through 2025 and 2026. |
| What gets measured | Body weight, blood sugar, cholesterol fractions and blood pressure. | The same, plus visceral fat, which is tracked separately. |
| Approval status | The compound is the active ingredient in an FDA approved prescription product. | Still investigational. Not approved by the FDA. |
| What North & North supplies | Research material only, 10mg and 30mg, >99% purity. | Research material only, 10mg and 30mg, >99% purity. |
Reading the research
What Each One Is Good For Studying
Retatrutide
The one at the edge. If the question is what the third receptor actually adds, this is the compound the field is asking it with, and the answers are still arriving.
Where things stand
Approval Status, Plainly
Tirzepatide is the active ingredient in prescription medications approved by the FDA for chronic weight management. North & North offers Tirzepatide as a separate research product, not the approved finished drug product.
Retatrutide remains under active clinical study and has not been approved by the FDA.
Both are supplied here as research material only. Nothing on this page is a claim about what either compound does for anyone.
- Jastreboff et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med, July 2022. SURMOUNT-1.
- Jastreboff et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial. N Engl J Med, August 2023.
- U.S. Food and Drug Administration. Approval announcement for chronic weight management.
Go deeper
Full Research on Each
Catalog access
Create a Free Account
Create a quick and easy free account to shop Tirzepatide and Retatrutide and other peptides.
Free to create. You will verify your email address before the catalog opens.